Diethyldithiocarbamate, a novel immunomodulator, prolongs survival in autoimmune MRL- lpr lpr mice

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

MRL- lpr lpr mice die at an early age from a spontaneously developing systemic lupus erythematosus-like disease and are characterized by massive lymphadenopathy, hyperproliferation of Lyt-2 L3T4 (null) T cells, decreased responses to mitogens, thymic atrophy, and very high serum autoantibody levels. Diethyldithiocarbamate (DTC), an immunomodulator suggested to enhance T cells, was used to treat 12-week-old female MRL- lpr lpr mice (25 mg/kg/week). DTC treatment significantly prolonged survival (50% mortality, 43 weeks vs 20 weeks). Increased survival was associated with decreased lymphadenopathy, decreased proliferation of null cells, restoration of impaired mitogen responses, decreased thymic atrophy, and decreased serum levels of anti-DNA and anti-histone antibodies. Studies of cell surface antigen phenotype demonstrated increased expression of Lyt-2 and macrophage surface antigens. No effect on L3T4 single staining cells was observed. These results show that DTC significantly alters the disease course in these mice and suggest that DTC may be a useful treatment for autoimmune disease.

Original languageEnglish (US)
Pages (from-to)242-254
Number of pages13
JournalClinical Immunology and Immunopathology
Volume55
Issue number2
DOIs
StatePublished - 1990

Fingerprint

Ditiocarb
Immunologic Factors
Null Lymphocytes
Surface Antigens
Mitogens
Atrophy
T-Lymphocytes
Antinuclear Antibodies
Serum
Systemic Lupus Erythematosus
Autoantibodies
Histones
Autoimmune Diseases
Macrophages
Staining and Labeling
Phenotype
Mortality
Lymphadenopathy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

@article{d63e7814409f48e1924f478d2f8373db,
title = "Diethyldithiocarbamate, a novel immunomodulator, prolongs survival in autoimmune MRL- lpr lpr mice",
abstract = "MRL- lpr lpr mice die at an early age from a spontaneously developing systemic lupus erythematosus-like disease and are characterized by massive lymphadenopathy, hyperproliferation of Lyt-2 L3T4 (null) T cells, decreased responses to mitogens, thymic atrophy, and very high serum autoantibody levels. Diethyldithiocarbamate (DTC), an immunomodulator suggested to enhance T cells, was used to treat 12-week-old female MRL- lpr lpr mice (25 mg/kg/week). DTC treatment significantly prolonged survival (50{\%} mortality, 43 weeks vs 20 weeks). Increased survival was associated with decreased lymphadenopathy, decreased proliferation of null cells, restoration of impaired mitogen responses, decreased thymic atrophy, and decreased serum levels of anti-DNA and anti-histone antibodies. Studies of cell surface antigen phenotype demonstrated increased expression of Lyt-2 and macrophage surface antigens. No effect on L3T4 single staining cells was observed. These results show that DTC significantly alters the disease course in these mice and suggest that DTC may be a useful treatment for autoimmune disease.",
author = "Halpern, {Melissa D} and Hersh, {Evan M} and Yocum, {David E.}",
year = "1990",
doi = "10.1016/0090-1229(90)90100-5",
language = "English (US)",
volume = "55",
pages = "242--254",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Diethyldithiocarbamate, a novel immunomodulator, prolongs survival in autoimmune MRL- lpr lpr mice

AU - Halpern, Melissa D

AU - Hersh, Evan M

AU - Yocum, David E.

PY - 1990

Y1 - 1990

N2 - MRL- lpr lpr mice die at an early age from a spontaneously developing systemic lupus erythematosus-like disease and are characterized by massive lymphadenopathy, hyperproliferation of Lyt-2 L3T4 (null) T cells, decreased responses to mitogens, thymic atrophy, and very high serum autoantibody levels. Diethyldithiocarbamate (DTC), an immunomodulator suggested to enhance T cells, was used to treat 12-week-old female MRL- lpr lpr mice (25 mg/kg/week). DTC treatment significantly prolonged survival (50% mortality, 43 weeks vs 20 weeks). Increased survival was associated with decreased lymphadenopathy, decreased proliferation of null cells, restoration of impaired mitogen responses, decreased thymic atrophy, and decreased serum levels of anti-DNA and anti-histone antibodies. Studies of cell surface antigen phenotype demonstrated increased expression of Lyt-2 and macrophage surface antigens. No effect on L3T4 single staining cells was observed. These results show that DTC significantly alters the disease course in these mice and suggest that DTC may be a useful treatment for autoimmune disease.

AB - MRL- lpr lpr mice die at an early age from a spontaneously developing systemic lupus erythematosus-like disease and are characterized by massive lymphadenopathy, hyperproliferation of Lyt-2 L3T4 (null) T cells, decreased responses to mitogens, thymic atrophy, and very high serum autoantibody levels. Diethyldithiocarbamate (DTC), an immunomodulator suggested to enhance T cells, was used to treat 12-week-old female MRL- lpr lpr mice (25 mg/kg/week). DTC treatment significantly prolonged survival (50% mortality, 43 weeks vs 20 weeks). Increased survival was associated with decreased lymphadenopathy, decreased proliferation of null cells, restoration of impaired mitogen responses, decreased thymic atrophy, and decreased serum levels of anti-DNA and anti-histone antibodies. Studies of cell surface antigen phenotype demonstrated increased expression of Lyt-2 and macrophage surface antigens. No effect on L3T4 single staining cells was observed. These results show that DTC significantly alters the disease course in these mice and suggest that DTC may be a useful treatment for autoimmune disease.

UR - http://www.scopus.com/inward/record.url?scp=0025217929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025217929&partnerID=8YFLogxK

U2 - 10.1016/0090-1229(90)90100-5

DO - 10.1016/0090-1229(90)90100-5

M3 - Article

VL - 55

SP - 242

EP - 254

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -